select a format

Single User License
USD 2000 INR 128240
Site License
USD 4000 INR 256480
Corporate User License
USD 6000 INR 384720

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Uveal Melanoma-Pipeline Review, H1 2015

Uveal Melanoma-Pipeline Review, H1 2015


  • Products Id :- GMDHC6424IDB
  • |
  • Pages: 86
  • |
  • March 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Uveal Melanoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Uveal Melanoma-Pipeline Review, H1 2015', provides an overview of the Uveal Melanoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveal Melanoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Uveal Melanoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Uveal Melanoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Uveal Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Uveal Melanoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Uveal Melanoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Uveal Melanoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Uveal Melanoma Overview 7

Therapeutics Development 8

Pipeline Products for Uveal Melanoma-Overview 8

Pipeline Products for Uveal Melanoma-Comparative Analysis 9

Uveal Melanoma-Therapeutics under Development by Companies 10

Uveal Melanoma-Therapeutics under Investigation by Universities/Institutes 11

Uveal Melanoma-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Uveal Melanoma-Products under Development by Companies 15

Uveal Melanoma-Products under Investigation by Universities/Institutes 16

Uveal Melanoma-Companies Involved in Therapeutics Development 17

Array BioPharma Inc. 17

AstraZeneca PLC 18

Celldex Therapeutics, Inc. 19

Eli Lilly and Company 20

GlaxoSmithKline plc 21

Novartis AG 22

Pfizer Inc. 23

Spectrum Pharmaceuticals, Inc. 24

Uveal Melanoma-Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Combination Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

binimetinib-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

crizotinib-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Dendritic Cell Therapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

emibetuzumab-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

glembatumumab vedotin-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

merestinib-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

nutlin-3-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

pasireotide LAR-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

selumetinib sulfate-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

sotrastaurin acetate-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

sunitinib malate-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

trametinib dimethyl sulfoxide + uprosertib-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

vincristine sulfate-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Uveal Melanoma-Recent Pipeline Updates 65

Uveal Melanoma-Dormant Projects 83

Uveal Melanoma-Product Development Milestones 84

Featured News & Press Releases 84

Jun 01, 2013: AstraZeneca's New Therapy Selumetinib Improves Progression-Free Survival And Shrink Tumors In Metastatic Uveal Melanoma, Researchers Report 84

Appendix 85

Methodology 85

Coverage 85

Secondary Research 85

Primary Research 85

Expert Panel Validation 85

Contact Us 85

Disclaimer 86

List of Tables

Number of Products under Development for Uveal Melanoma, H1 2015 8

Number of Products under Development for Uveal Melanoma-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

Uveal Melanoma-Pipeline by Array BioPharma Inc., H1 2015 17

Uveal Melanoma-Pipeline by AstraZeneca PLC, H1 2015 18

Uveal Melanoma-Pipeline by Celldex Therapeutics, Inc., H1 2015 19

Uveal Melanoma-Pipeline by Eli Lilly and Company, H1 2015 20

Uveal Melanoma-Pipeline by GlaxoSmithKline plc, H1 2015 21

Uveal Melanoma-Pipeline by Novartis AG, H1 2015 22

Uveal Melanoma-Pipeline by Pfizer Inc., H1 2015 23

Uveal Melanoma-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 24

Assessment by Monotherapy Products, H1 2015 25

Assessment by Combination Products, H1 2015 26

Number of Products by Stage and Target, H1 2015 28

Number of Products by Stage and Mechanism of Action, H1 2015 30

Number of Products by Stage and Route of Administration, H1 2015 32

Number of Products by Stage and Molecule Type, H1 2015 34

Uveal Melanoma Therapeutics-Recent Pipeline Updates, H1 2015 65

Uveal Melanoma-Dormant Projects, H1 2015 83

List of Figures

Number of Products under Development for Uveal Melanoma, H1 2015 8

Number of Products under Development for Uveal Melanoma-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Assessment by Monotherapy Products, H1 2015 25

Number of Products by Top 10 Targets, H1 2015 27

Number of Products by Stage and Top 10 Targets, H1 2015 27

Number of Products by Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Top 10 Routes of Administration, H1 2015 31

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 32

Number of Products by Top 10 Molecule Types, H1 2015 33

Number of Products by Stage and Top 10 Molecule Types, H1 2015 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Array BioPharma Inc.

AstraZeneca PLC

Celldex Therapeutics, Inc.

Eli Lilly and Company

GlaxoSmithKline plc

Novartis AG

Pfizer Inc.

Spectrum Pharmaceuticals, Inc.

Uveal Melanoma Therapeutic Products under Development, Key Players in Uveal Melanoma Therapeutics, Uveal Melanoma Pipeline Overview, Uveal Melanoma Pipeline, Uveal Melanoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com